Dykema Guides Ocean Biomedical in Launch as Publicly Traded Company

Dykema, a leading national law firm, today announced that a team of its attorneys, led by Kate Bechen, guided firm client Ocean Biomedical, Inc., in its launch as a publicly traded company on the Nasdaq Capital Market this week following the completion of its business combination with special purpose acquisition company (SPAC), Aesther Healthcare Acquisition Corp. The combined company will trade under the symbol “OCEA.”

The merger between Aesther and Ocean Biomedical, a medical research innovation incubator, will accelerate the development of its core assets in oncology, fibrosis, and infectious diseases. Based in Providence, Rhode Island, Ocean Biomedical is a company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets by utilizing its funding to move new, promising therapeutic candidates from research universities and medical centers to the next stages in their development.

“Our team was thrilled to close this deal and ring the opening bell at Nasdaq with this amazing company. We are in a market where companies are facing significant headwinds in their efforts to go public so successfully bringing Ocean to the public markets is very rewarding,” said Bechen. “Ocean Biomedical is doing important, innovative work in the biomed sector, and it’s exciting to see their reach expand through this combination with Aesther.”

Along with Bechen, Dykema attorneys from several offices and practices worked on the deal, including the core team of Tom Vaughn, Andrew Frost, Robin Lehninger, Julie D’Angelo, Jill Knutson, Joe DeHondt, Katherine Spiser, Timothy Caprez, Mark Malven, Jessica Zeratsky, Jonathan Meulemans, Hallie Heath, and Reid Hazelton.